Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients W...

Por Home, Philip D.
Publicado em 2013

Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations

Por Home, Philip D.
Publicado em 2013

Management of type 2 diabetes: NICE guidelines

Por Sibal, Latika, Home, Philip D
Publicado no Clin Med (Lond) (2009)

Repeatability of measurements and sources of variability in tests of cardiovascular autonomic function

Por Lawrence, Gillian P, Home, Philip D, Murray, Alan
Publicado em 1992

Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes

Por Sibal, Latika, Agarwal, Sharad C, Home, Philip D
Publicado em 2011

The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease

Por Sibal, Latika, Agarwal, Sharad C, Home, Philip D, Boger, Rainer H
Publicado em 2010

Observational Study of the Association of First Insulin Type in Uncontrolled Type 2 Diabetes with Macrovascular and Microvascular Disease

Por Hall, Gillian C., McMahon, Alex D., Carroll, Dawn, Home, Philip D.
Publicado em 2012

Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interven...

Por Hajjaji, Issam, Shah, Siddharth, Li, Yuxiu, Prusty, Vinay, Benabbas, Youcef, Home, Philip D.
Publicado em 2014

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A...

Por Bolli, Geremia B., Landgraf, Wolfgang, Bosnyak, Zsolt, Melas‐Melt, Lydie, Home, Philip D.
Publicado no Diabetes Obes Metab (2020)

A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria

Por Sibal, Latika, Agarwal, Sharad C, Schwedhelm, Edzard, Lüneburg, Nicole, Böger, Rainer H, Home, Philip D
Publicado em 2009

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy

Por Lepercq, Jacques, Lin, Jay, Hall, Gillian C., Wang, Edward, Dain, Marie-Paule, Riddle, Matthew C., Home, Philip D.
Publicado em 2012

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)...

Por Home, Philip D., Bergenstal, Richard M., Bolli, Geremia B., Ziemen, Monika, Rojeski, Maria, Espinasse, Melanie, Riddle, Matthew C.
Publicado no Diabetes Obes Metab (2017)

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%

Por Owens, David R., Landgraf, Wolfgang, Frier, Brian M., Zhang, Mei, Home, Philip D., Meneghini, Luigi, Bolli, Geremia B.
Publicado no Diabetes Obes Metab (2019)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes:...

Por Bolli, Geremia B., Kerr, David, Thomas, Reena, Torlone, Elisabetta, Sola-Gazagnes, Agnès, Vitacolonna, Ester, Selam, Jean Louis, Home, Philip D.
Publicado em 2009

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes:...

Por Komajda, Michel, Curtis, Paula, Hanefeld, Markolf, Beck-Nielsen, Henning, Pocock, Stuart J, Zambanini, Andrew, Jones, Nigel P, Gomis, Ramon, Home, Philip D
Publicado em 2008

Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections From a Diabetes Care Editors’ E...

Por Cefalu, William T., Buse, John B., Del Prato, Stefano, Home, Philip D., LeRoith, Derek, Nauck, Michael A., Raz, Itamar, Rosenstock, Julio, Riddle, Matthew C.
Publicado no Diabetes Care (2014)

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

Por Komajda, Michel, McMurray, John J.V., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Pocock, Stuart J., Curtis, Paula S., Jones, Nigel P., Home, Philip D.
Publicado em 2010

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

Por Riddle, Matthew C., Bolli, Geremia B., Home, Philip D., Bergenstal, Richard M., Ziemen, Monika, Muehlen-Bartmer, Isabel, Wardecki, Marek, Vinet, Laetitia, Jeandidier, Nathalie, Yki-Järvinen, Hannele
Publicado no Diabetes Technol Ther (2016)

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

Por Birkeland, Kåre I., Home, Philip D., Wendisch, Ulrich, Ratner, Robert E., Johansen, Thue, Endahl, Lars A., Lyby, Karsten, Jendle, Johan H., Roberts, Anthony P., DeVries, J. Hans, Meneghini, Luigi F.
Publicado em 2011

Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum

Por Cefalu, William T., Bray, George A., Home, Philip D., Garvey, W. Timothy, Klein, Samuel, Pi-Sunyer, F. Xavier, Hu, Frank B., Raz, Itamar, Van Gaal, Luc, Wolfe, Bruce M., Ryan, Donna H.
Publicado no Diabetes Care (2015)